Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers
Will you be recommending relugolix due to rapid suppression of testosterone and lower risk of cardiovascular events?
In the HERO trial, relugolix, a highly selective oral GnRH antagonist, demonstrated faster and sustained castration, faster testosterone recovery, and a reduction in major adverse cardiovascular events when compared to leuprolide.
Answer from: Radiation Oncologist at Community Practice
Once FDA approved, it will be an option; but I'm not sure what the cost to the patient will be, as it is an oral drug and that may be a limiting factor.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
We still have the option of monthly degarelix if one is looking for a GnRH antagonist.